CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
TAK-700 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01084655
NCT01084655Phase 2Completed
CompareCT.gov

An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Millennium Pharmaceuticals, Inc.·interventional·Posted Mar 10, 2010·Updated Jul 30, 2019

In Brief

A Phase 2 clinical trial evaluating TAK-700, Docetaxel, and 1 other intervention for Prostate Cancer. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This is an open-label, multicenter, Phase 1/2 study of TAK-700 in combination with docetaxel and prednisone that will evaluate the safety and pharmacokinetics (PK) of the combination and will allow estimation of prostate-specific antigen (PSA) response in men with metastatic castration-resistant prostate cancer (mCRPC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2010
Enrollment StartJul 1, 2010
Primary CompletionJan 1, 2013
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 16.3 years ago

Interventions

TAK-700drug

TAK-700 with docetaxel and prednisone on a continuous schedule.

Docetaxeldrug

TAK-700 with docetaxel and prednisone on a continuous schedule.

Prednisonedrug

TAK-700 with docetaxel and prednisone on a continuous schedule.